Pyridones
Concept
Vocabulary Service
Overview
subject area of
-
A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure. Academic Article
-
A Survey of the Use of Empiric Novel Anticoagulants During Investigation of Stroke Academic Article
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score Academic Article
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer Academic Article
-
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
-
Acute management of bleeding in patients on novel oral anticoagulants Academic Article
-
Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study Academic Article
-
Advantages and limitations of the new anticoagulants Academic Article
-
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial Academic Article
-
An assay to measure levels of factor Xa inhibitors in blood and plasma Academic Article
-
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
-
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
-
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation Academic Article
-
Another piece in the pirfenidone puzzle Academic Article
-
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone Academic Article
-
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis Academic Article
-
Anticoagulation for Mechanical Heart Valves Academic Article
-
Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned Academic Article
-
Apixaban for Extended Treatment of Venous Thromboembolism Academic Article
-
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review Academic Article
-
Apixaban in Acute Coronary Syndromes Academic Article
-
Apixaban in Patients with Atrial Fibrillation Academic Article
-
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer Academic Article
-
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement Academic Article
-
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients Academic Article
-
Apixaban versus Enoxaparin in Medically Ill Patients Academic Article
-
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial Academic Article
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Academic Article
-
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Academic Article
-
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Academic Article
-
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Academic Article
-
Appropriate Apixaban Dosing Academic Article
-
Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study Academic Article
-
BIOSYNTHESIS OF MIMOSINE: INCORPORATION OF ASPARTIC ACID INTO THE PYRIDONE NUCLEUS Academic Article
-
Beyond Unfractionated Heparin and Warfarin Academic Article
-
Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin Academic Article
-
Bleeding and antidotes in new oral anticoagulants Academic Article
-
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience Academic Article
-
Bleeding with direct oral anticoagulants vs warfarin: clinical experience Academic Article
-
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment Academic Article
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial Academic Article
-
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials Academic Article
-
Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism Academic Article
-
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
-
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin Academic Article
-
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications Academic Article
-
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure Academic Article
-
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development Academic Article
-
Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis Academic Article
-
Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study Academic Article
-
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? Academic Article
-
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis Academic Article
-
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents Academic Article
-
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) Academic Article
-
Deferiprone and hepatic fibrosis Academic Article
-
Deferiprone in Friedreich ataxia: A 6-Month randomized controlled trial Academic Article
-
Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature Academic Article
-
Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home Academic Article
-
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis Academic Article
-
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies Academic Article
-
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials Academic Article
-
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Academic Article
-
Direct oral anticoagulants: evidence and unresolved issues Academic Article
-
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Academic Article
-
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial Academic Article
-
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy Academic Article
-
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect Academic Article
-
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty Academic Article
-
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study Academic Article
-
Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study Academic Article
-
Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis Academic Article
-
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis Academic Article
-
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis Academic Article
-
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial Academic Article
-
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial Academic Article
-
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study Academic Article
-
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials Academic Article
-
Evolving use of new oral anticoagulants for treatment of venous thromboembolism Academic Article
-
Extended treatment of venous thromboembolism. Academic Article
-
Factor Xa and thrombin as targets for new oral anticoagulants Academic Article
-
Fluorofenidone Offers Improved Renoprotection at Early Interventions during the Course of Diabetic Nephropathy in db/db Mice via Multiple Pathways Academic Article
-
Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies Academic Article
-
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy Academic Article
-
How I treat target-specific oral anticoagulant–associated bleeding Academic Article
-
In AF, apixaban reduced stroke or systemic embolism compared with warfarin, regardless of patient age Academic Article
-
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation Academic Article
-
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Academic Article
-
Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials Academic Article
-
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation Academic Article
-
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants Academic Article
-
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation Academic Article
-
Laboratory measurement of the direct oral anticoagulants Academic Article
-
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Academic Article
-
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES Academic Article
-
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels Academic Article
-
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension Academic Article
-
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study Academic Article
-
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting Academic Article
-
Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS
2
and CHA
2
DS
2
-VASc Scores in Patients With Atrial Fibrillation Academic Article
-
Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation Academic Article
-
Monitoring and reversal of direct oral anticoagulants Academic Article
-
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
-
Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma Academic Article
-
New Anticoagulants for Atrial Fibrillation Academic Article
-
New Anticoagulants for Treatment of Venous Thromboembolism Academic Article
-
New Anticoagulants for the Prevention of Thromboembolism Academic Article
-
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
-
New anticoagulants in atrial fibrillation management Conference Paper
-
New oral anticoagulant agents – general features and outcomes in subsets of patients Academic Article
-
New oral anticoagulants and oculoplastic surgery Academic Article
-
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Academic Article
-
New oral anticoagulants in elderly patients Academic Article
-
New oral anticoagulants: not quite there yet Academic Article
-
Novel Oral Anticoagulants: A Focused Review for Stroke Physicians Academic Article
-
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism Academic Article
-
Novel oral anticoagulants in gastroenterology practice Academic Article
-
Novel oral anticoagulants in secondary prevention of stroke Academic Article
-
Optimal Prescription of the Lower Dose of Apixaban Academic Article
-
Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants Academic Article
-
Oral Apixaban for the Treatment of Acute Venous Thromboembolism Academic Article
-
Oral Direct Factor Xa Inhibitors Academic Article
-
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease Academic Article
-
Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation Academic Article
-
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation Academic Article
-
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation Academic Article
-
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial Academic Article
-
Overview of the New Oral Anticoagulants Academic Article
-
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer Academic Article
-
Perioperative management of patients who are receiving a novel oral anticoagulant Academic Article
-
Periprocedural Management of Oral Anticoagulation Academic Article
-
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy Academic Article
-
Peroxiredoxin 1 inhibits the oxidative stress induced apoptosis in renal tubulointerstitial fibrosis Academic Article
-
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients Academic Article
-
Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management Academic Article
-
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Academic Article
-
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction Academic Article
-
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose Academic Article
-
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation Academic Article
-
Potential of new anticoagulants in patients with cancer Academic Article
-
Practical aspects of new oral anticoagulant use in atrial fibrillation Academic Article
-
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban Academic Article
-
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study Academic Article
-
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies Academic Article
-
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study Academic Article
-
Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis Academic Article
-
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Academic Article
-
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial Academic Article
-
Reducing the risk of recurrent stroke in patients with AF Academic Article
-
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation Academic Article
-
Response. Academic Article
-
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions Academic Article
-
Review: In renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants Academic Article
-
Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit) Academic Article
-
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants Academic Article
-
Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study Academic Article
-
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro Academic Article
-
Rivaroxaban for the prevention and treatment of venous thromboembolism Academic Article
-
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Academic Article
-
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation Academic Article
-
Selective cleavage of heparin using aqueous 2-hydroxypyridine: Production of an aldose-terminating fragment with high anticoagulant activity Academic Article
-
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials Academic Article
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Academic Article
-
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial Academic Article
-
Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease Academic Article
-
Stroke prevention in atrial fibrillation: Closing the gap Academic Article
-
Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape Academic Article
-
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease Academic Article
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations Academic Article
-
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale Academic Article
-
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial Academic Article
-
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study Academic Article
-
The top 4 advances in antithrombotic care in the last year Academic Article
-
The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload Academic Article
-
Therapeutic targets in idiopathic pulmonary fibrosis Academic Article
-
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding Academic Article
-
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update Academic Article
-
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis Academic Article
-
Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014 Academic Article
-
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review Academic Article
-
Venous thromboembolism management: where do novel anticoagulants fit? Academic Article
-
Well-managed warfarin is superior to NOACs Response Academic Article